If your Mounjaro pen failed or you can't tell whether the dose went in, don't start a second injection on your own: keep the pen and its carton, report it to Lilly online or at 1-800-545-5979 (9 a.m. to 5 p.m. ET, weekdays), and ask your prescriber or pharmacist how to handle this week's dose. If you already injected again and think you took too much, call your healthcare provider or Poison Help at 1-800-222-1222, or go to the nearest emergency room.

Novo Nordisk's dated cash prices for every Ozempic and Wegovy dose, the FDA-approved uses those prices require, what 12 months of fills add up to, and what compounded semaglutide is advertised for, with what FDA says about it.

Most people on tirzepatide need better meals more than pills. Experts advise a daily multivitamin with minerals if you eat very little or lose weight very fast, and folic acid if you could become pregnant. Skip weight-loss boosters, and know the warning signs that need action right away.

Anthem pays for Wegovy, Zepbound or Foundayo for weight loss only when a plan's benefits include weight-loss drugs, and its September 2026 criteria usually ask for 6 months in a supervised diet and exercise program first. None of the three is on Anthem's individual or Small Group Select drug lists, and Anthem approves Ozempic and Mounjaro only for type 2 diabetes.

No GLP-1 medicine is FDA-approved for weight loss unless you have obesity, or overweight with a weight-related condition. This page shows which approved uses don't depend on weight, what the trials behind the approvals did not test, and the risks of taking one off-label.

What IRS rules, plan administrators and CareCredit's own terms say about paying for GLP-1 medication with an HSA, FSA or CareCredit: which companies take the card, what to do if your plan might cover the drug, 2026 and 2027 limits, a paperwork checklist and worked examples.

You can switch, but it takes a new Zepbound prescription, and the label has no rule for converting a compounded dose, so your prescriber sets where you start. If you pay yourself, Lilly's LillyDirect charges $299 to $449 for 28 days with on-time refills (as of October 3, 2026), and none of the plan criteria we read counts earlier compounded use.

Zepbound and Mounjaro come as pens and as vials; for injection, Wegovy and Ozempic come as pens, and their labels also list prefilled syringes but no vial. If your prescriber gives you a choice, a pen spares you from drawing each dose into a syringe, the step most of the compounded semaglutide dosing errors FDA described in 2024 involved.

About 6% of starting weight by week 8, roughly 12 pounds from 200 (our arithmetic), is the average among people still taking Zepbound (tirzepatide) in SURMOUNT-1, a trial in adults with obesity, or overweight plus a weight-related condition, and no diabetes; more than a third had not yet lost 5%, and the trial reports we checked give no first-month average. In U.S. health records, adults with overweight or obesity who started Mounjaro had lost 5.3% on average at 3 months and 8.2% at 6 months, counting people who stopped, or 5.9% and 10.1% among those still taking it.

In the 27 states that use Centene's standard drug list, Ambetter's 2026 lists leave out Wegovy, Zepbound and Foundayo, and Centene approves Ozempic and Mounjaro only for type 2 diabetes, with prior authorization. Most California plans cover weight-loss drugs under strict rules; New York's contract allows exception requests, but we found nothing showing how a weight-loss request would be decided there. See what the lists, contracts and policies say, and how to check and appeal for your own plan.

A personal or family history of medullary thyroid cancer (MTC), or MEN 2, still rules out these GLP-1 medicines after thyroid removal; otherwise the reason for surgery matters, so ask your prescriber and bring your pathology report. Below: the labels, and what to ask about levothyroxine.

What DoD's Operation Supplement Safety tells service members, including the Guard and Reserve, about Wegovy, Zepbound and Ozempic; what DoD's accession standards and drug tests say; and how TRICARE, the VA and CHAMPVA cover GLP-1 drugs as of October 2026, with TRICARE's and the VA's routes after a denial.

Medicaid generally pays for GLP-1 drugs such as Ozempic, Mounjaro and Trulicity for type 2 diabetes, but paying for Wegovy, Zepbound or Foundayo for weight loss is each state's choice. As of October 3, 2026, we confirmed 10 states that still do. Here is what most of them require, what people in other states can still do, how to check your own list and how to appeal a denial.

Whether UnitedHealthcare pays for Ozempic, Mounjaro, Wegovy, Zepbound or Foundayo depends on why it is prescribed, which plan you have and sometimes your state. This page sets out UHC's rules for employer, Marketplace, Medicare and Community Plan members from UHC's and Medicare's own documents, explains the Medicare GLP-1 Bridge, and covers what to do after a denial.

Yes, a licensed doctor may prescribe compounded tirzepatide when the legal conditions are met, but it has no FDA approval and some doctors decline. For an injection at or near an approved strength, your prescriber usually has to document a difference that matters medically for you; a lower price does not count.

What Zepbound, Mounjaro and compounded tirzepatide cost without insurance as of October 3, 2026: LillyDirect's price at each dose, a dated year of fills, membership and prescriber fees, and seven compounded offers totaled for 12 months.

What FDA-approved GLP-1 medicines cost without insurance as of October 3, 2026, from $149 a month for the starting doses of two daily pills, how to get a prescription without a membership fee, which drugmaker discounts each kind of buyer can use, and what FDA says about compounded semaglutide and tirzepatide, which are not FDA-approved.

The Zepbound approval criteria published by CVS Caremark, Express Scripts, Prime and FEP Blue as of October 2026, the federal deadlines for a decision, and step-by-step appeals for work, individual, federal employee and Medicare drug plans.

As of October 4, 2026: Lilly's card can cut a covered fill to as little as $25 (limits apply). Without coverage, Lilly's cash price is $149 to $299 a month by dose (on-time refills at the top two doses). Medicare's Bridge is $50 a month if you qualify.

Prices, auto-renewal, notice to cancel and refund rules at ten online GLP-1 programs and drugmaker pharmacies, from TrimRx, Willow and Embody to Ro and LillyDirect, each taken from the company's own site on October 3, 2026. PlexusDx, which publishes this page, is compared alongside them on the basis of its own statements.

No agency ranks compounded tirzepatide providers. This page explains what the law allows after the shortage, how to check any provider's prescriber and pharmacy, which claims FDA calls misleading, when an approved drug or your own doctor is the better route, and PlexusDx's own answers.

GLP-1 helps control blood sugar and appetite; GLP-2 helps the gut lining grow. Tirzepatide is not a GLP-2 drug, and as of October 2026 no GLP-2 drug is approved for weight loss.